Zolbetuximab + mFOLFOX6 as first-line (1 L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study - Shitara, K; Lordick, F; Bang, Y-J (J Clin Oncol, 2023)
et al.